

Organized by

ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ  
ΜΟΡΙΑΚΗΣ ΘΕΡΑΠΕΥΤΙΚΗΣ  
ΤΟΥ ΚΑΡΚΙΝΟΥ



# Masterclass on Tumor Biomarkers

4-5 July 2024

GOLDEN AGE Hotel | Athens

... acidology  
... 2009, 16(2014) / the benefit  
... that contains the genetic  
... development and functional  
... molecules is the long arm of the  
... When compared to a gene, the  
... for a code, since a contains the  
... to construct other components of  
... and RNA molecules. The DNA  
... its genetic information are called  
... sequences have structural  
... involved in regulating the use of this  
... genetic information.

Chemically, DNA consists of two long polymers of simple units called nucleotides, with backbones made of sugars and phosphate groups joined by ester bonds. These two strands run in opposite directions to each other and are therefore anti-parallel. Attached to each sugar is one of four types of molecules called bases. It is the sequence of these bases that encodes information. This information is read using the genetic code to specify the sequence of the amino acids within proteins. The code is read by copying stretches of DNA into the related genetic acid RNA, in a process called transcription.

Within cells, DNA is organized into long structures called chromosomes. These chromosomes are duplicated before cells divide, in a process called DNA replication. Eukaryotic organisms (animals, plants, fungi, and protists) store most of their DNA inside their cell nuclei and some of their DNA in organelles, such as mitochondria or chloroplasts. [1] In contrast, prokaryotes (bacteria and archaea) store their DNA only in the cytoplasm. Within the chromosomes, chromatin proteins such as histones compact and organize DNA. These compact structures guide the interactions between DNA and other proteins, helping control which parts of the DNA are transcribed.

... DNA exists in many po  
... include A-DNA, B-DNA  
... only B-DNA and Z-DNA  
... functional organisms,  
... directly depends on the  
... the amount and direct  
... modification of the bases,  
... of metal ions, as well a  
... solution.[29]

... The first published rep  
... patterns—and also B-  
... Patterson transforms t  
... amount of structural  
... DNA.[30][31] An analy  
... by Wilkins et al.in 195  
... diffraction/scattering  
... fibers in terms of squa  
... interperiod. Watson  
... molecular modeling an  
... diffraction patterns to  
... double-helix.[7]

... Although the B-DNA  
... conditions found in ce  
... conformation but a fa  
... conformations[34] tha  
... well present in hydra  
... molecular paracrystal  
... disorder.[35][36]

... Compared to B-DNA, th  
... is a handed site as w  
... a shallow major gro  
... occurs under non-phy  
... dehydrated samples o  
... produces chain hybrid  
... as well as in enzyme-  
... segments of DNA, wh  
... chemically modified,  
... larger change in conf  
... methylation an

Secretariat



Scientific | Cultural Events & Publications

www.scep.gr



# Masterclass on Tumor Biomarkers

## TUMOR BIOMARKERS FOR PRECISION ONCOLOGY

Thursday July 4, 2024

08.00-08.45 *Registration*

08.45-09.00 *Welcome*

09.00-10.50 **Session 1: The reality of Precision Medicine**

Chairs: **G. Nasioulas, Ch. Panopoulos**

09.00-09.20 Precision Oncology: The hope to improve better outcomes in daily clinical practice

**A. Boutis**

09.20-09.40 The key role of pathologist in the molecular diagnostic procedure

**P. Foukas**

09.40-10.00 The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

**E. Papadopoulou**

10.00-10.20 Mutational profiling for Precision Medicine using NGS in the clinical practice

**G. Nasioulas**

10.20-10.40 Gene fusions and RNA sequence

**K. Roumelioti**

10.40-10.50 Comments: **P. Konstantoulakis, N. Tsoukalas, F. Papageorgiou**

10.50-11.20 *Coffee break*

11.20-12.30 **Session 2: Clinically emerging Biomarkers**

Chairs: **A. Klinakis, K. Ploiarchopoulou**

11.20-11.40 The biological background of Homologous Recombination deficiency (HRD)

**Th. Rambias**

11.40-12.00 GSS/HRD score: Its clinical value as a biomarker

**P. Konstantoulakis**

12.00-12.20 The utility of ESR1 mutations as a biomarker for personalized hormone treatment in breast cancer

**N. Pisimisis**

12.20-12.30 Comments: **P. Katsaounis, M. Kaparelou**

12.30-13.30 **Lectures**

Chairs: **V. Georgoulis, F. Papageorgiou**

12.30-13.00 Understanding the biology of tumor heterogeneity

**Cedric Guedard**

13.00-13.30 Liquid biopsy for the evaluation of tumor heterogeneity in the clinical practice

**E. Lianidou**

13.30-14.30 *Light lunch*



# Masterclass on Tumor Biomarkers

## 14.30-16.40 Session 3: Liquid biopsy for Precision Oncology (I)

Chairs: **G. Kallergi, Ph. Koinis**

- |             |  |                        |
|-------------|--|------------------------|
| 14.30-14.50 | Clinical utility of circulating tumor cells                      | <b>Ath. Markou</b>     |
| 14.50-15.10 | Clinical utility of ctDNA  | <b>F. Papageorgiou</b> |
| 15.10-15.30 | Recommendations for the use of ctDNA in clinical practice        | <b>Th. Tegos</b>       |
| 15.30-15.50 | Emerging value of CfDNA for cancer screening and early detection | <b>G. Kapetsis</b>     |
| 15.50-16.10 | Detection and analysis of circulating tumor cells                | <b>G. Kallergi</b>     |
| 16.10-16.30 | Detection and analysis of ctDNA                                  | <b>A. Voutsina</b>     |
| 16.30-16.40 | Comments: <b>E. Kotteas, A. Boutis, D.Zyllis, A. Strati</b>      |                        |

## 16.40-17.00 *Coffee break*

## 17.00-18.10 Session 4: Liquid biopsy for Precision Oncology (II)

Chairs: **Ath. Markou, E. Galani**

- |             |  |                         |
|-------------|--|-------------------------|
| 17.00-17.20 | Monitoring of MRD using ctDNA  | <b>S. Giannoulakis</b>  |
| 17.20-17.40 | Monitoring of osimertinib treatment in EGFR mutant NSCLC using liquid biopsy | <b>A. Ntzifa</b>        |
| 17.40-18.00 | Clinical applications of ctDNA in breast cancer                              | <b>E. Karatrasoglou</b> |
| 18.00-18.10 | Comments: <b>E. Fergadis, K. Ploiarchopoulou</b>                             |                         |

## 18.10-19.20 Session 5: Biomarkers in GI tumors

Chair: **E. Lianos**

- |             |   |                           |
|-------------|---|---------------------------|
| 18.10-18.30 | Clinical applications of ctDNA in CRC                   | <b>G. Papaxoinis</b>      |
| 18.30-18.50 | Emerging druggable biomarkers in Upper GI tumors        | <b>D. Symeonidis</b>      |
| 18.50-19.10 | Rare druggable gene mutations in CRC                    | <b>K. Ploiarchopoulou</b> |
| 19.10-19.20 | Comments: <b>P. Papakostas, M. Demiri, M. Theochari</b> |                           |

## Friday July 5, 2024

## 09.00-10.30 Session 6: Biomarkers in Immuno-Oncology

Chairs: **P. Foukas, P. Konstantoulakis**

- |             |  |                         |
|-------------|--|-------------------------|
| 09.00-09.20 | The prognostic and predictive value of TILs                                    | <b>I. Pateras</b>       |
| 09.20-09.40 | The heterogeneous value of PD-L1 in the daily clinical practice                | <b>I. Vamvakaris</b>    |
| 09.40-10.00 | Intergrating MSI/MMR testing in the clinical practice                          | <b>N. Asimakopoulou</b> |
| 10.00-10.20 | The importance of Tumor Mutation Burden (TMB) in the treatment decision making | <b>G. Tsaousis</b>      |
| 10.20-10.30 | Comments: <b>F. Koinis, E. Kontopodis, Th. Tegos</b>                           |                         |

## 10.30 *Closing Remarks*

# Masterclass on Tumor Biomarkers

## Γενικές Πληροφορίες

### Διοργάνωση



ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ ΜΟΡΙΑΚΗΣ ΘΕΡΑΠΕΥΤΙΚΗΣ ΤΟΥ ΚΑΡΚΙΝΟΥ

### Τίτλος

Masterclass on Tumor Biomarkers

### Ημερομηνία διεξαγωγής

4-5 Ιουλίου 2024

### Τόπος διεξαγωγής

Ξενοδοχείο Golden Age, Αθήνα

### Γλώσσα

Η επίσημη γλώσσα συνεδρίου είναι η Ελληνική

### Κόστος Εγγραφής

Δωρεάν

### Γραμματεία Οργάνωσης Συνεδρίου

Η γραμματεία θα λειτουργεί κατά τη διάρκεια του συνεδρίου σύμφωνα με το επιστημονικό πρόγραμμα



Scientific | Cultural Events & Publications

T +30 210 7240039 E [info@scep.gr](mailto:info@scep.gr) [www.scep.gr](http://www.scep.gr) [in](#) [LiveTIME](#) [fb](#)